BIOLOGICS-
Pet
Our focus
The studies in workpackage 4 (WP4) will focus on the use of imaging of the in vivo distribution and target interaction of biologics with positron emission tomography (PET), fluorescence imaging and mass spectrometry imaging (MSI) to obtain insight in the safety, efficacy and side-effects of new biologics in the early stage of the drug development process. To use these techniques for this specific purpose, members of WP4 will develop and test labelling agents to label biologics with 89Zr and fluoreophores. The labelled biologics will be studied to elucidate those aspects of the biodistribution and interaction with the target tissue to assess the safety and clinical translation of novel biologics. The studies In WP4 will include in vitro studies, preclinical studies in animal models and clinical studies.
The key objectives
- Develop and evaluate new methods to label biologics with 89Zr.
- Demonstrate whether advanced imaging techniques are able to identify characteristics of new biologics important for evaluation of the safety and clinical translation.
- Investigate the possibilities to monitor therapeutic function of novel biologics by PET imaging.
Imaging methods and tracer development
- 89Zr labelling
- PET Imaging
- Fluorescent Imaging
- MS Imaging
Imaging studies animal models
- 89Zr labelled biologics
- 18F labelled biologics
- Fluorescent labelled biologics
Clinical imaging studies
- 89Zr labelled biologics
- 18F labelled biologics
Our Partners for biologics-PET
